Astellas Pharma Inc. Newsletter
-
Targeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps
31 Dec 2025 14:08 GMT
… Daiichi Sankyo, personal fees from Astellas, outside the submitted work. The … EC, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of … Targeted protein degradation: advances in drug discovery and clinical practice. Signal …
-
Induced Pluripotent Stem Cell (iPSC) Market Competition Analysis 2026: How Players Are Shaping Growth
02 Jan 2026 09:30 GMT
… precision disease modelling, personalized drug screening, and regenerative … cells for applications in drug discovery, contract development … address niche applications in drug discovery, regenerative medicine, … Bio Inc. (2%)
o Astellas Pharma Inc. (1%)
o …
-
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
29 Dec 2025 21:40 GMT
… Pharma. About Royalty Pharma Founded in 1996, Royalty Pharma … leading global pharmaceutical companies. Royalty Pharma has assembled … Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi … royaltypharma.com. Royalty Pharma Investor Relations and Communications …
-
Primary Biliary Cholangitis Market Competition Analysis 2025: How Players Are Shaping Growth
02 Jan 2026 01:15 GMT
… Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co., … Inc U.S. Food and Drug Administration (FDA) approval (June … Ahead?
•Focusing on orphan drug designations to enhance therapeutic …
-
<![CDATA[ICYMI: Highlights From ASCO GU 2025]]>
01 Jan 2026 21:12 GMT
… regulatory compliance for high-risk drug approvals, and optimize treatment … (PARP) inhibitor, and enzalutamide (Xtandi; Astellas Pharma/;Pfizer), an androgen receptor … the real world, particularly concerning drug delivery, quality assurance, and efficacy …
-
Urinary Incontinence Therapeutics Market Set To Explode Opportunities, Future Scope 2025-2032 | Astellas Pharma, Pfizer
03 Dec 2025 12:48 GMT
… also negatively impacts demand for drug-based therapies.
Some urinary incontinence … incontinence therapeutics are developing newer drug classes like beta-3 … therapeutics market report include:
Pfizer
Astellas Pharma
AbbVie
Eli Lilly
Allergan
Teva …
-
Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer
18 Dec 2025 06:45 GMT
(RTTNews) - Astellas Pharma Inc. and Pfizer Inc. announced … ), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda …
-
Aviceda Therapeutics to advance eye disease drug despite Phase IIb loss
16 Dec 2025 18:53 GMT
… no statistical difference compared to Astellas Pharma’s Izervay (avacincaptad pegol), … and Drug Administration (FDA) approval in August 2023, Apellis Pharmaceuticals’ Syfovre … Arena.
Other companies investigating drugs for GA include Boehringer Ingelheim …
-
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
16 Dec 2025 12:15 GMT
… the U.S. Food and Drug Administration and has an action … companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio … Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer …
-
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
15 Dec 2025 13:24 GMT
… has granted roxadustat Orphan Drug Designation for the treatment … (MDS). “The Orphan Drug Designation granted to roxadustat … the U.S. following drug approval.
About Myelodysplastic … AstraZeneca or licensed to Astellas. Astellas and FibroGen are collaborating …
About
© 1995-2026